Ardelyx stock decline attributed to setback in Xphozah appeal
Seeking Alpha ·
Ardelyx ( ARDX ) shares fell ~6% on Friday after the company lost an appeal against the Health and Human Services Department regarding a Medicare decision that eliminated Part D coverage for its kidney disease therapy, Xphozah.
DYAX Investor Sentiment
Bullish (Long) 69% · Bearish (Short) 31%
418 participants
Related News
- Cineverse reaffirms fiscal 2027 guidance of $115M-$120M revenue and $10M-$20M adjusted EBITDA following IndiCue and Giant acquisitions
- 애플 Vision Pro 하드웨어 총괄, OpenAI로 이직
- Microsoft Has Fallen 25% This Year: What Could Push MSFT Back to $500?
- SpaceX granted early termination from FTC for Mesh Optical merger
- Uber expands U.S. driver background checks, updates screening rules
- OpenAI Just Signaled It Might Delay Its IPO. AI Stocks Are Tumbling. Is the Bubble Bursting?